Literature DB >> 28515930

Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.

Nobuki Furubayashi1, Takahito Negishi1, Hidenori Iwai1, Kei Nagase1, Kenichi Taguchi2, Mototsugu Shimokawa3, Motonobu Nakamura1.   

Abstract

The present study aimed to determine the adequate pelvic lymph node dissection (PLND) range for Japanese males undergoing radical prostatectomy. A total of 467 Japanese patients who underwent antegrade radical prostatectomy at the National Kyushu Cancer Center (Fukuoka, Japan) were retrospectively reviewed. The patients were divided into two groups according to the PLND extent: The standard (obturator + internal iliac nodes) group and the expanded (standard + additional nodes) group, which accounted for 64.5% (301/467) and 35.5% (166/467) of the patients, respectively. No differences were observed in the preoperative and postoperative characteristics of the two groups. In addition, there was no difference in PSA recurrence between the two groups. There were no differences between the standard and expanded groups in the low-, intermediate- and high-risk groups (P=0.1456, P=0.1581, P=0.2125, respectively). The median number of lymph node dissection was 13 and 19, in the standard and expanded groups respectively (P<0.0001). However, regarding the number of lymph node metastases and the rate of patients with lymph node metastasis, no significant difference was observed between the standard and expanded groups (P=0.4219 and P=0.4257, respectively). According to multivariate analysis, a significant difference in the presence of lymph node metastasis (hazard ratio 3.547; P=0.0247), but not in the PLND extent, was detected in patients with prostate specific antigen failure (P=0.0655). When expanding the dissection extent, the number of dissected lymph nodes increases, but is not associated with the number or rate of positive lymph nodes. Thus, the current dissection range is considered to be appropriate for Japanese men undergoing radical prostatectomy.

Entities:  

Keywords:  pelvic lymph node dissection; prostate cancer; prostate specific antigen; prostate specific antigen recurrence; radical prostatectomy

Year:  2017        PMID: 28515930      PMCID: PMC5431281          DOI: 10.3892/mco.2017.1204

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  17 in total

1.  Advances in biomedical imaging.

Authors:  C M Tempany; B J McNeil
Journal:  JAMA       Date:  2001-02-07       Impact factor: 56.272

2.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

Review 3.  The role of lymphadenectomy in prostate cancer.

Authors:  Fiona C Burkhard; Urs E Studer
Journal:  Urol Oncol       Date:  2004 May-Jun       Impact factor: 3.498

Review 4.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

Review 5.  The role of pelvic lymphadenectomy for prostate cancer--therapeutic?

Authors:  M Wagner; M Sokoloff; S Daneshmand
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

6.  Should pelvic lymph node dissection be performed with radical prostatectomy? No.

Authors:  Michael S Cookson
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

7.  Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases.

Authors:  Joanna Perry-Keene; Peter Ferguson; Hemamali Samaratunga; John N Nacey; Brett Delahunt
Journal:  Histopathology       Date:  2013-10-11       Impact factor: 5.087

Review 8.  MR imaging and MR spectroscopy in prostate cancer management.

Authors:  Sharyn Katz; Mark Rosen
Journal:  Radiol Clin North Am       Date:  2006-09       Impact factor: 2.303

9.  Is pelvic lymph node dissection required at radical prostatectomy for low-risk prostate cancer?

Authors:  Koji Mitsuzuka; Takuya Koie; Shintaro Narita; Yasuhiro Kaiho; Takahiro Yoneyama; Sadafumi Kawamura; Tatsuo Tochigi; Chikara Ohyama; Tomonori Habuchi; Yoichi Arai
Journal:  Int J Urol       Date:  2013-02-06       Impact factor: 3.369

Review 10.  Pelvic lymph node dissection in prostate cancer.

Authors:  Alberto Briganti; Michael L Blute; James H Eastham; Markus Graefen; Axel Heidenreich; Jeffrey R Karnes; Francesco Montorsi; Urs E Studer
Journal:  Eur Urol       Date:  2009-03-10       Impact factor: 20.096

View more
  1 in total

Review 1.  Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?

Authors:  Bartosz Małkiewicz; Paweł Kiełb; Jakub Karwacki; Róża Czerwińska; Paulina Długosz; Artur Lemiński; Łukasz Nowak; Wojciech Krajewski; Tomasz Szydełko
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.